InfoQ
Netflix Reworks Conductor for 420 Million Monthly Workflow Executions and 10X Larger Workflows Leela Kumili
Netflix has reworked its Conductor workflow orchestration engine to handle larger workloads, increasing supported workflow size from about 2,500 to 30,000 tasks and reducing p99 workflow evaluation latency by about 40%. Conductor 4.0 separates workflow metadata from task data, moves evaluation to asynchronous processing, and introduces dynamic worker allocation and concurrency controls. By Leela Kumili
11 September 2026 at 22:17

Netflix Reworks Conductor for 420 Million Monthly Workflow Executions and 10X Larger Workflows

InfoQ

11 September 2026 at 22:17

Netflix has reworked its Conductor workflow orchestration engine to handle larger workloads, increasing supported workflow size from about 2,500 to 30,000 tasks and reducing p99 workflow evaluation latency by about 40%. Conductor 4.0 separates workflow metadata from task data, moves evaluation to asynchronous processing, and introduces dynamic worker allocation and concurrency controls.

By Leela Kumili

Nature Medicine
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial Omar Nadeem · David M. Cordas dos Santos · Sophie Magidson · Jeffrey Matous · Eva Medvedova · Elizabeth O’Donnell · Robert A. Redd · Yuxin Liu · Shonali Midha · Adam S. Sperling · Frances Arters · Christine Davie · Caroline Ricciardi · Rosa Toenges · Nayda Bidikian · Subear Hussein · Jean-Baptiste Alberge · Sungjae Kim · Lorena Pantano-Rubino · Francesco Corrado · Hannah Ashton · Daniel Addonizio · Siham Mohamed · Ashlee Sturtevant · Marjorie Marto · Amy Bergeron · Francesco Malfona · Kevin Panaro · Paul G. Richardson · Jerome Ritz · Lorenzo Trippa · Irene M. Ghobrial
Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-wIn the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.
11 September 2026 at 08:00

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Nature Medicine

By: Omar Nadeem · David M. Cordas dos Santos · Sophie Magidson · Jeffrey Matous · Eva Medvedova · Elizabeth O’Donnell · Robert A. Redd · Yuxin Liu · Shonali Midha · Adam S. Sperling · Frances Arters · Christine Davie · Caroline Ricciardi · Rosa Toenges · Nayda Bidikian · Subear Hussein · Jean-Baptiste Alberge · Sungjae Kim · Lorena Pantano-Rubino · Francesco Corrado · Hannah Ashton · Daniel Addonizio · Siham Mohamed · Ashlee Sturtevant · Marjorie Marto · Amy Bergeron · Francesco Malfona · Kevin Panaro · Paul G. Richardson · Jerome Ritz · Lorenzo Trippa · Irene M. Ghobrial

11 September 2026 at 08:00

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w

In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.